Drug Database
DI

diphtheria and tetanus combined vaccine (adsorbed)

✓ Approved

Beijing Tiantan Biological Products · 细胞治疗 · 细胞治疗

什么是 diphtheria and tetanus combined vaccine (adsorbed)?

diphtheria and tetanus combined vaccine (adsorbed) 是一种细胞治疗,由Beijing Tiantan Biological Products研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)。

药物档案

公司Beijing Tiantan Biological Products
药物类别细胞治疗, 疫苗
给药途径Injectable (Others)
状态Approved

治疗适应症

diphtheria and tetanus combined vaccine (adsorbed) 针对 2 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Infections and infestationsDiphtheria✓ Approved
Infections and infestationsTetanus✓ Approved

相关研究文献

PubMedJournal of clinical immunology2026-11-17

SIMPATHY Study: Specific Antibody Response to Typhim Vi Polysaccharide as a Surrogate Marker of Infectious Risk in Secondary Immunodeficiency Associated with B Cell Cancer.

Peixoto-Rodriguez Alejandro A, Melero Josefa J, de Andrés Ana A, López-Granados Eduardo E et al.

Recurrent and severe infections represent a major cause of morbidity and mortality of secondary immunodeficiency (SID) associated with B-cell lymphoproliferative syndromes (B-CLPD). Nevertheless, immunological evaluation and prophylactic interventions are often delayed until infectious complications occur. Early vaccination is therefore relevant not only because it provides protection during the initial phases of B-CLPD, but also because it enables the identification of patients at higher risk of infection. In this context, assessment of antigen-specific humoral response has been proposed as a useful biomarker for identifying patients with greater clinical vulnerability. We conducted SIMPATHY (Secondary Immunodeficiency Multicentric study on the Antibody Production to Typhi vaccine), a multicentre, retrospective, observational study including 128 individuals with B-CLPD, classified according to the presence or absence of severe and/or recurrent infections, as well as healthy controls. Specific IgG antibody responses to Streptococcus pneumoniae (13-valent conjugate, Prevenar), Salmonella typhi (Typhim Vi), and tetanus toxoid vaccines were assessed at baseline and 4-weeks after vaccination. Among 128 individuals analysed, patients with B-CLPD showed significant immunological and clinical differences compared to healthy controls, particularly in vaccine-specific antibody responses and lymphocyte subsets. B-CLPD patients with recurrent or severe infections exhibited markedly reduced pre-vaccination anti-pneumococcal (p = 0.03) and post-vaccination anti-pneumococcal (p = 0.001) and anti-Salmonella typhi Vi titers (p = 0.1), highlighting impaired vaccine-specific antibody responses as potential predictors of infection risk. An immunological classification identified two subgroups within B-CLPD, predominant antibody defect and combined immune defect, with a trend toward higher respiratory infection rates in the latter, suggesting broader immune dysfunction.

PMID 43040101
阅读全文 →
PubMedBMC infectious diseases2026-11-17

Clinical characteristics and indicators associated with poor in-hospital prognosis among children with severe pertussis in Shandong Province, China (2022-2024).

Wang Ping P, Li Jian J

Pertussis is a life-threatening respiratory infection among young infants. This retrospective study enrolled only children already diagnosed with severe pertussis. We aimed to describe clinical characteristics and identify indicators associated with poor in‑hospital prognosis within this severe cohort, rather than exploring predictors for progression from mild to severe pertussis. A retrospective observational study was conducted among 80 children diagnosed with severe pertussis who were hospitalized between January 2022 and December 2024. Clinical data, laboratory results, treatment, and outcomes were collected. Multivariate logistic regression and receiver operating characteristic (ROC) curve analysis were applied to screen indicators associated with composite poor in-hospital prognosis and evaluate their prognostic performance.Composite poor in-hospital prognosis was defined as new in-hospital adverse events including invasive mechanical ventilation, pertussis encephalopathy with persistent neurological sequelae, or all-cause in-hospital death; 6 out of 80 participants met this composite endpoint. White blood cell count was included as a continuous variable in multivariate regression. The optimal cutoff of > 30 × 10⁹/L was derived from ROC analysis for descriptive and potential bedside reference only and was not used for regression modelling. The median age was 4 months and 19 days (range, 1 month 14 days to 5 years); 65.0% (52/80) of patients were infants ≤ 3 months who could not receive routine diphtheria, pertussis, and tetanus (DPT) vaccine. All patients presented paroxysmal cough, and 95% had inspiratory whoop. Leukocytosis (WBC > 20 × 10⁹/L) was observed in 45.0% of children; 75.0% had patent foramen ovale (PFO), and 18.80% developed secondary cardiac abnormalities. Erythromycin combination therapy carried a significantly higher risk of liver dysfunction than monotherapy (36.40% vs. 8.60%, P < 0.05). Multivariate logistic regression identified three independent correlates of composite poor prognosis: unvaccinated status (OR = 4.2, 95%CI 1.8-9.6, P = 0.001), mixed bacterial-viral co-infection (OR = 3.5, 95%CI 1.2-10.1, P = 0.023), and elevated continuous white blood cell count (OR = 5.1, 95%CI 2.3-11.4, P < 0.001). Given the limited number of poor-prognosis events (n = 6), these adjusted associations should be interpreted cautiously as exploratory findings.ROC analysis using continuous WBC count yielded an AUC of 0.678, whereas the combined prognostic model derived from multivariable logistic regression achieved an AUC of 0.689. Infants aged ≤ 3 months constituted the majority of children hospitalized with severe pertussis. After adjusting for age-related vaccination eligibility, unvaccinated status, mixed bacterial-viral co-infection, and higher white blood cell count were independently associated with poor in-hospital prognosis. ROC analysis demonstrated only modest discriminative performance of these indicators; at present, they serve merely as potential references and require external validation before any clinical application. Not applicable.

PMID 43040268
阅读全文 →
PubMedGeriatrie et psychologie neuropsychiatrie du vieillissement2026-11-17

[2026 vaccination schedule for adults aged 65 years and older: towards comprehensive vaccine-based prevention in older age].

Corroyer-Simovic Bénédicte B

The 2026 French vaccination schedule redefines geriatric prevention, extending its focus beyond the prevention of infectious diseases to the preservation of independence and functional health. Yet vaccination coverage in France remains inadequate. To address immunosenescence, the strategy prioritizes comprehensive protection against respiratory infections caused by influenza viruses, SARS-CoV-2, pneumococcus and respiratory syncytial virus (RSV). For influenza, guidelines recommend the preferential use of enhanced vaccines-either high-dose or adjuvanted formulations-to improve protection in older adults and reduce hospital admissions. Covid-19 boosters remain essential for this vulnerable population, with the adjuvanted recombinant protein vaccine Nuvaxovid® available alongside mRNA vaccines. Pneumococcal prevention is considerably simplified: a single dose of the 21-valent pneumococcal conjugate vaccine (PCV21, Capvaxive®) is recommended for all adults aged 65 years and older. This vaccine covers the serotypes responsible for 83.5% of invasive pneumococcal disease cases in France in 2024. RSV vaccination is indicated for adults aged 75 years and older and for those aged 65 years and older with cardiopulmonary comorbidities, providing protection against severe disease and reducing hospital admissions during winter. Beyond respiratory infections, vaccination against herpes zoster with the adjuvanted recombinant vaccine Shingrix® is recommended for all adults aged 65 years and older. Recent data associate this vaccination not only with the prevention of postherpetic neuralgia but also with a reduced risk of stroke. Tdap-IPV boosters remain essential in the context of recent pertussis epidemics and the persistent risk of tetanus in older adults. Vaccine coadministration is safe and should be offered to improve coverage and reduce the number of visits required. When vaccination records are unavailable, the priority is to proceed with vaccination rather than delay protection. This proactive, integrated approach aims to address inadequate vaccination coverage, reduce mortality and preserve independence in older adults.

PMID 43042679
阅读全文 →
PubMedBMC immunology2026-11-17

In Silico affinity profiling differentiates consensus vaccine sequences where genetic and structural similarity fail: a case study on HCV E2 genotypic and pan-genotypic antigens.

Mohabati Reyhaneh R, Teimoori-Toolabi Ladan L, Azadmanesh Kayhan K, Roohvand Farzin F et al.

The World Health Organization's goal to eradicate hepatitis C by 2030 remains unattainable without an effective vaccine. Consensus generation combined with layering has the potential to introduce vaccines against highly variable viruses like HCV. However, this approach yields numerous candidates that require in vivo testing. Profiling the affinity of these candidates to monoclonal antibodies via in silico methods can help reduce the number of candidates. In this study, we evaluated the differentiating power of in silico affinity profiling on two previously reported genotypic consensus sequences (NOTC1 and NOTC2) and two newly generated pan-genotypic sequences (L1-CON and L2-CON), each derived using distinct consensus generation algorithms. Structural models of these sequences were generated via homology modelling and simulated within a canonical ensemble. The resulting average structures were then used as inputs for antigen-antibody docking studies against all reported antibody structures known to bind to each epitope in the HCV E2 protein. Docking results for epitope II revealed lower binding energies for NOTC1 compared to NOTC2 (p = 0279) and J-2a (p = 0.0132) consistent with their reported in vivo performance. This discrimination was not reproduced in genetic distance from the common ancestor of Genotype 1 and also structural similarity between protein models and crystalographed antigen. Notably, neither sequence nor structural similarity correlated with the docking outcomes, highlighting the predictive value of the proposed affinity profiling pipeline as an initial assessment tool for vaccine candidates.

PMID 43040467
阅读全文 →
PubMedBMC public health2026-11-17

Post-introduction evaluation of COVID-19 vaccine deployment in Ghana: lessons learnt to inform future new vaccine introductions and strengthen public health readiness, 2023.

Amponsa-Achiano Kwame K, Shen Angela K AK, Baiden Laryea Eunice E, Carlton Julie Garon JG et al.

On March 2nd, 2021, Ghana, the first country to receive vaccines from the COVAX facility, began its COVID-19 vaccination using a complex multi-phased approach, to reach target populations. We evaluated the vaccine deployment to document best practices challenges and lessons for future new vaccine introductions and public health emergency readiness. We conducted a mixed methods post-introduction evaluation, purposively sampling 36 facilities from 12 districts in six regions. Adapting the World Health Organization's COVID-19 Post-Introduction Evaluation tool, we conducted a cross-sectional survey using a structured questionnaire, reviewed programme records, observed practices, and interviewed purposively selected health workers, immunization managers and partners who supported vaccine deployment. We performed summary descriptive statistics on quantitative data, thematic analysis on qualitative data, and triangulated the results. As of March 2023, more than 70% of the target population (15 years and older) had received at least one dose, while more than 50% had completed the primary series. Vaccine deployment was built on the existing immunisation programme and functional coordinating bodies. Cold chain capacity was revamped with ultra-low-temperature freezers, while 33.3% of surveyed districts adjusted waste disposal systems to accommodate COVID-19 vaccine introduction. Door-to-door delivery and demand generation through varied risk communication and community engagement strategies improved vaccine access. Electronic data platforms were established, surge capacity improved, and healthcare and community workers were trained. Initial unpredictable vaccine supplies limited vaccination efforts. Changing vaccine information affected health workers' ability to engage communities with up-to-date guidance. While vaccine safety monitoring systems were in place, reporting knowledge varied among health workers, and 36% of surveyed facilities had ever documented and reported COVID-19 vaccine-related adverse events following immunisation. Challenges with electronic data systems limited timely access to and use of granular service-delivery data for decision-making. Ghana leveraged existing immunisation and emergency-response systems to make substantial progress in COVID-19 vaccine deployment. Coordination, cold chain expansion, flexible service delivery, demand generation and workforce mobilisation supported implementation. Irregular vaccine supply, data system challenges, variable adverse event reporting, waste management pressure and misinformation challenged deployment. These findings provide lessons for adult immunisation, life-course vaccination and future public health emergency readiness.

PMID 43040294
阅读全文 →
PubMedACI open2026-11-17

Enhancing Human Papillomavirus Vaccine Communication with Mobile Health: Usability Insights from Caregivers and Health Care Providers.

Reisher Elizabeth E, Anyanwu Evangel E, Figliomeni Jonathan J, Honcoop Adrien A et al.

Despite the effectiveness of the human papillomavirus (HPV) vaccine in preventing cancer, uptake remains suboptimal, especially among rural and underserved populations. Digital communication tools such as mobile health (mHealth) applications have the potential to improve access to accurate vaccine information and support shared decision-making. This study aimed to assess the usability, acceptability, and perceived usefulness of a newly developed mHealth app for HPV vaccine communication in comparison to the Centers for Disease Control and Prevention's (CDC) HPV vaccine Web site. Using a mixed-methods design and guided by the Health Belief Model and the mHealth Agile Development and Evaluation Lifecycle, caregivers, and health care providers were randomized to explore both the CDC Web site and the mHealth app in alternating order. Participants were asked to complete a session answering HPV vaccine questions with each tool and completed the mHealth App Usability Questionnaire, Propensity to Trust, and NASA Task Load Index (NASA-TLX) after each session. Qualitative questions were asked after each session to capture additional feedback on items such as navigation and readability. Transcripts were analyzed using inductive thematic analysis. Quantitative results showed no difference between the tools in terms of being easy to use, requiring similar amounts of effort, and trust in the tool. Qualitative themes revealed that participants appreciated the app's streamlined navigation, tailored content, and readability. In contrast, the CDC Web site was seen as credible but often difficult to navigate, especially when searching for nuanced or specific vaccine information. Tailored mHealth tools developed with user-centered design principles may better meet the informational and usability needs of caregivers and health care providers compared with existing web-based resources. These findings support further development and integration of mHealth tools into vaccine communication strategies to enhance HPV vaccine communication.

PMID 43042227
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多diphtheria and tetanus combined vaccine (adsorbed)